This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Filipits, M. Articles by Pirker, R. Search for Related Content PubMed PubMed Citation Articles by Filipits, M. Articles by Pirker, R.

Expression of the Lung Resistance Protein Predicts Poor Outcome in Patients with Multiple Myeloma¹

Department of Internal Medicine I, Division of Oncology [M. F., J. D., G. P., T. S., J. A., R. K., H. K., H. H., R. P.] and Division of Hematology [H. G.], University of Vienna, A-1090 Vienna, and First Department of Internal Medicine with Medical Oncology, Wilhelminenspital, A-1160 Vienna [J. S., H. L.], Austria

Expression of the lung resistance protein (LRP) is associated with resistance to various anticancer drugs including melphalan and, therefore, may affect the clinical outcome in multiple myeloma (MM). To determine the clinical significance of LRP, we have compared LRP expression in bone marrow plasma cells with clinical parameters including response to chemotherapy and survival of previously untreated patients with MM (n = 72). LRP expression immunocytochemically assessed by means of the LRP-56 monoclonal antibody was positive (10% staining plasma cells) in 44 (61%) samples. There was no correlation between LRP expression and age, sex, type of the paraprotein, serum creatinine, stage, ß₂-microglobulin, serum lactate dehydrogenase, or C-reactive protein. However, LRP expression was more frequently observed in patients with a p53 deletion than in those without such a deletion (P = 0.01). The overall response rate for all of the patients evaluable for response to induction chemotherapy (n = 58) was 67%. The response rate was 87% for patients without LRP expression but only 54% for patients with LRP expression (P = 0.01). Kaplan-Meier analysis revealed that patients with LRP expression had a shorter overall survival (median, 33 months) than those without LRP expression (median not reached; P = 0.04). These data show that LRP expression is an important marker for clinical drug resistance and predicts a poor outcome in MM.

This article has been cited by other articles:

				H. Ovaa, B. M. Kessler, U. Rolen, P. J. Galardy, H. L. Ploegh, and M. G. Masucci Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells PNAS, February 24, 2004; 101(8): 2253 - 2258. [Abstract] [Full Text] [PDF]

				R. G. Jenner, K. Maillard, N. Cattini, R. A. Weiss, C. Boshoff, R. Wooster, and P. Kellam Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile PNAS, September 2, 2003; 100(18): 10399 - 10404. [Abstract] [Full Text] [PDF]

				M. Filipits, G. Pohl, T. Stranzl, H. Kaufmann, J. Ackermann, H. Gisslinger, H. Greinix, A. Chott, and J. Drach Low p27Kip1 Expression Is an Independent Adverse Prognostic Factor in Patients with Multiple Myeloma Clin. Cancer Res., February 1, 2003; 9(2): 820 - 826. [Abstract] [Full Text] [PDF]

				N. Ohno, A. Tani, K. Uozumi, S. Hanada, T. Furukawa, S. Akiba, T. Sumizawa, A. Utsunomiya, T. Arima, and S.-i. Akiyama Expression of functional lung resistance-related protein predicts poor outcome in adult T-cell leukemia Blood, August 15, 2001; 98(4): 1160 - 1165. [Abstract] [Full Text] [PDF]

				M. Filipits, U. Jaeger, I. Simonitsch, C. Chizzali-Bonfadin, H. Heinzl, and R. Pirker Clinical Relevance of the Lung Resistance Protein in Diffuse Large B-Cell Lymphomas Clin. Cancer Res., September 1, 2000; 6(9): 3417 - 3423. [Abstract] [Full Text]